Christopher Medlock Doesn't Think Heron Therapeutics Inc (HRTX)'s Gains This Year Will Stop At A Mere 220%
Christopher Medlock James' Partner Fund Management recently initiated a position in Heron Therapeutics Inc (NASDAQ:HRTX), together with its affiliated funds, according to a 13G form filed with the Securities...